

Sub
E2

~~29. An isolated polypeptide comprising a mature portion of a protein as encoded by the vascular endothelial growth factor-3 (VEGF-3) cDNA clone contained in ATCC Deposit No.~~

~~97116.~~

30. An isolated polypeptide comprising 50 contiguous amino acids of SEQ ID NO:2.

31. The isolated polypeptide of claim 30, wherein said polypeptide comprises amino acids 69 to 82 of SEQ ID NO:2.

32. The isolated polypeptide of claim 31, wherein said polypeptide comprises amino acids 46 to 123 of SEQ ID NO:2.

D1

33. The isolated polypeptide of claim 32, wherein said polypeptide comprises amino acids 30 to 221 of SEQ ID NO:2.

34. An isolated polypeptide, comprising a fragment of at least 50 amino acids of SEQ ID NO:2, wherein said fragment binds an antibody having specificity for the polypeptide of SEQ ID NO:2.

Sub
E3

~~35. An isolated polypeptide, comprising a fragment of at least 50 amino acids encoded by the cDNA contained in ATCC Deposit No. 97116, wherein said fragment binds an antibody having specificity for the polypeptide of SEQ ID NO:2.~~

36. An isolated polypeptide, comprising a fragment of at least 50 amino acids of SEQ ID NO:2, wherein said fragment has angiogenic activity.

Sub
E4

37. An isolated polypeptide, comprising a fragment of at least 50 amino acids encoded by the cDNA contained in ATCC Deposit No. 97116, wherein said fragment has angiogenic activity.

38. The isolated polypeptide of claim 26, further comprising a heterologous polypeptide.

39. The isolated polypeptide of claim 27, further comprising a heterologous polypeptide.

D1

40. The isolated polypeptide of claim 28, further comprising a heterologous polypeptide.

41. The isolated polypeptide of claim 29, further comprising a heterologous polypeptide.

42. The isolated polypeptide of claim 30, further comprising a heterologous polypeptide.

43. The isolated polypeptide of claim 31, further comprising a heterologous polypeptide.

44. The isolated polypeptide of claim 32, further comprising a heterologous polypeptide.

45. The isolated polypeptide of claim 33, further comprising a heterologous polypeptide.

46. The isolated polypeptide of claim 34, further comprising a heterologous polypeptide.

47. The isolated polypeptide of claim 35, further comprising a heterologous polypeptide.

48. The isolated polypeptide of claim 36, further comprising a heterologous polypeptide.

49. The isolated polypeptide of claim 37, further comprising a heterologous polypeptide.

50. The isolated polypeptide of claim 28, which is produced or contained in a recombinant cell.

51. The isolated polypeptide of claim 29, which is produced or contained in a recombinant cell.

52. The isolated polypeptide of claim 30, which is produced or contained in a recombinant cell.

53. The isolated polypeptide of claim 34, which is produced or contained in a recombinant cell.

54. The isolated polypeptide of claim 35, which is produced or contained in a recombinant cell.

55. The isolated polypeptide of claim 36, which is produced or contained in a recombinant cell.

56. The isolated polypeptide of claim 37, which is produced or contained in a recombinant cell.

57. A pharmaceutical composition comprising the isolated polypeptide of claim 26 in a pharmaceutically acceptable carrier.

58. A pharmaceutical composition comprising the isolated polypeptide of claim 27 in a pharmaceutically acceptable carrier.

59. A pharmaceutical composition comprising the isolated polypeptide of claim 28 in a pharmaceutically acceptable carrier.

60. A pharmaceutical composition comprising the isolated polypeptide of claim 29 in a pharmaceutically acceptable carrier.

61. A pharmaceutical composition comprising the isolated polypeptide of claim 30 in a pharmaceutically acceptable carrier.

62. A pharmaceutical composition comprising the isolated polypeptide of claim 34 in a pharmaceutically acceptable carrier.